Clinical trial
A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With Investigator's Choice of Chemotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas With High Levels of GD2 Expression and Disease Progression During 1st Line Chemotherapy
NCT06669013 is registered in ClinicalTrials.gov with N.N. Petrov National Medical Research Center of Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With Investigator's Choice of Chemotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas With High Levels of GD2 Expression and Disease Progression During 1st Line Chemotherapy
- Lead sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 20, 2021
- Completion date
- September 30, 2025
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
alveolar rhabdomyosarcoma, bone sarcoma, embryonal rhabdomyosarcoma